ELN 2024 recommendations: Genetic risk stratification in patients with AML receiving less-intensive therapies
Dohner et al. recently published ELN 2024 genetic risk classification for patients with AML receiving less-intensive therapies in Blood.
Related Articles
The Diagnosis and Prevalence of Secondary AML
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
Reducing the Burden of Radiation | Cancer Today
Shorter courses of more intense radiation therapy mean fewer visits and less cost for patients.
Clinical Research Training Course
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
FDA Grants Priority Review to Dato-DXd in Advanced EGFR-Mutated NSCLC
The FDA granted priority review to datopotamab deruxtecan in advanced EGFR-mutated NSCLC after prior therapies, with a decision expected by July 12, 2025.
Exploring emerging biomarkers and therapies for metaplastic breast cancer
Pooja Advani, MBBS, MD, Mayo Clinic, Jacksonville, FL, gives an overview of hypothesis-generating research on biomarkers and therapies for metaplastic breast cancer. While heterogeneity among…
MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease
Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.
Definitions | Division of Cancer Control and Population Sciences (DCCPS)
Who is a cancer survivor? Years ago, some suggested that the definition should only include people who were cancer-free for a minimum amount of time…
Welcome! You are invited to join a webinar: Challenges in Building a Translational Research Program. After registering, you will receive a confirmation email about joining the webinar.
Join the Women in Cancer Surgery Work Group for an in-depth discussion of the hurdles surgeons face as they set up a translational research program,…
2025 Orphan Drugs: PDUFA Dates and FDA Approvals
Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory…
